Polymyositis (PM) and dermatomyositis (DM) are characterized by chronic inflammation of skeletal muscle and are manifested, in their classic presentation, by proximal muscle weakness accompanied by elevations of the serum creatine kinase (CK) typical electromyography (EMG) changes with polyphasic potentials and muscle biopsy findings of a necrotizing, inflammatory process.' DM is distinguished from PM by a typical rash, usually red, scaly and plaque-like, over the knuckles, wrists, elbows, knees and ankle malleoli and violaceous lesions in the periorbital and trunk area.2 Most authors, however, consider DM and PM together since the disease course and muscle lesions are the same, whether skin lesions are present or not. 3 These diseases are of unknown aetiology and reltively rare but have been associated with a host of inciting agents, from infections4 to vaccines5 to malignancies' and involve a multitude of immunological abnormalities. 7 The classification scheme popularized by Bohan et al. 8'9 and modified by Whitaker4 appears in Table I . This review concentrates on types I, II, III and V.
Clinical manifestations
The clinical hallmark of PM/DM is weakness in the proximal muscles as well as in flexion of the neck and trunk. Patients usually notice lower extremity weakness first with difficulty rising from a squat or low chair or in climbing stairs. Upper extremity weakness follows with problems reaching above the head to comb the hair, hang clothes or reach cabinets. There is often noticeable sparing of both distal and facial muscles.2 Dysphagia is present in 10-15% of patients'" and predisposes to aspiration as well as being a marker for severe disease and a poor prognosis. One third of the patients show the unmistakable skin rash, with a purplish, dusky appearance, predominantly on the eyelids, cheeks and light- exposed areas. The rash may be patchy or confluent. It may also be seen on the extensor surface of the knees, elbows, knuckles and peri-ungally ( Figure 1 ). Periorbital oedema is an important physical finding in the diagnosis of DM and may be seen in the absence of other skin lesions. Calcinosis of subcutaneous tissues is a rare but dramatic complication. Widespread subcutaneous and muscle calcification, seen many years after the onset of PM, provide popular X-rays in examinations in the way of major disability. Some cases develop troublesome ulceration.
Another 5-10% of patients have pulmonary disease in the form of interstitial pulmonary fibrosis, respiratory muscle insufficiency or aspiration pneumonia. " Presentation ofinterstitial disease can be variable but patients frequently complain of fever, dyspnoea and non-productive cough, and there are usually basilar rales on physical examination. Findings on pulmonary function testing are thnse of a restrictive defect, reduced total lung capacit, limitation of diffusion and relative hypoemia.2 The most common chest X-ray findings are those of a diffuse reticulonodular pattern. Histologically there is alveolitis, septal fibrosis, infiltration by lymphocytes and plasma cells, hyperplasia of type II pneumocytes and increased numbers ofalveolar macrophages. 3 In a recent series from the Mayo Clinic pulmonary vasculitis was also seen frequently'4 although, in our own experience, pulmonary vasculitis is over-diagnosed. Like dysphagia, interstitial pulmonary disease seems Figure 1 Periungal lesions in polymyositis.
to be a poor prognostic feature. Rarely the pulmonary disorder precedes the muscle disease by months to years but when it follows the myositis it usually does so relatively early. '5 Respiratory muscle weakness, on the other hand, usually becomes manifest at the same time as generalized muscle weakness and is frequently associated with pharyngeal dysfunction and aspiration'3 Tachypnoea, weak cough and radiographic evidence of atelectasis are clues to the diagnosis.
Aspiration pneumonia is the most common pulmonary complication in PM/DM, affecting as many as 14% of patients,'3 and is an important cause of mortality.'4 Almost all of these patients have high dysphagia with nasal regurgitation and a weakness of the pharyngeal and upper oesophageal muscles of deglutition. Fortunately, the interstitial fibrosis as well as the respiratory pharyngeal muscle weakness generally shows some response to corticosteroid therapy. '6 Various types of cardiac conduction abnormalities have been described in PM. Fortunately, these are usually clinically silent. '7 In a large series, Bohan et al.'0 found arrhythmias in 6% of patients, bundle branch block in 5%, congestive heart failure in 3% and high grade block in 2%.
A local, nodular swelling in leg muscles is a rare variant in the presentation of PM, and when present usually precedes the generalized myopathy. ' Myoglobin, the respiratory protein of muscle cells, is released in massive amounts in PM/DM. Though not measured routinely, myoglobin levels, determined by radioimmunoassay, are in some ways a better measure ofdisease activity than CK.2' However, if one is going to follow myoglobin levels they must be drawn at the same time ofday because ofdiurnal variations.28 Myoglobinuria may be associated (rarely) with renal failure in patients with PM/DM, as with other causes of rhabdomyolysis. 29 In almost 80% of patients the EMG reveals low amplitude, short duration polyphasic potentials on voluntary contractions and fibrillation potentials at rest, all typical of myopathies." Nearly 10% of patients though have a normal EMG, possibly because of a lack of sufficient sampling sites, given the multifocal nature of PM/DM. It is necessary, therefore, to sample both proximal and distal muscle groups as well as paraspinal muscles.' As an aside, it is also important to draw enzyme levels before the EMG is done in order to avoid spurious CK elevations from needle-induced trauma.
The gold standard for diagnosis is the muscle biopsy. It typically shows necrosis and regeneration of muscle fibres with infiltration of perivascular and interstitial spaces by small and large lymphocytes, macrophages and plasma cells (Figure 3) .31 If the disease process has been chronic, accumulation of lipid in conjunction with muscle atrophy are seen. As a matter of practical importance, the biopsy should not be taken from an area near EMG sampling since histological changes that are needle-induced may be misleading.
Muscle scintigraphy has been used to localize biopsy sites in PM as it demonstrates increased uptake of 99m-technetium-labelled phosphate in damaged muscles, presumably because of the increased binding of the phosphate to calcium in such muscles.32 But, because this test is also positive in non-inflammatory myopathies and in trauma, its usefulness is limited in PM/DM outside ofidentifying appropriate muscles to biopsy. Fluorescein studies may provide the same information, as vascular permeability to fluorescein is increased in muscles with inflammatory changes. 33 There The evidence for a cell-mediated mechanism is even stronger than that for a iiumoral. Lymphocytes from adults with PM/DM are cytotoxic to muscle cells in tissue cultures, apparently because of sensitization to muscle antigens.4 This is not unlike the host-versusgraft response to muscle homografts. There is also activation of killer cells and the ratio of T-helper to T-suppressor cells is significantly elevated, in the range of 6:1 as opposed to the normal 2: 13 Furthermore, there is evidence of complementmediated vascular injury at least in DM. The membrane C5b9 attack complex has recently been shown to be deposited and then activated within the intramuscular microvasculature with resultant vasculopathy. 50 Despite the multiple derangements of the immune system in DM the mechanism for these derangements has continued to elude investigators.
Association with infection
There have been sporadic reports ofPM/DM developing in association with vaccination5 or a viral illness especially with Coxsackie viruses5",52 and human immunodeficiency virus.53" There is also an association with recent toxoplasmosis infections,55 but the question arises whether the toxoplasmosis caused PM or whether the PM, by virtue of its immunosuppressive nature, allowed for reactivation of latent toxoplasmosis, or other infections for that matter.
Association with malignancy
For over half a century there has been debate over the association of PM/DM with an occult malignancy. Despite multiple studies in the literature an exact relationship has never been established. Physicians have tended, nevertheless, to put their patients with a new diagnosis of PM/DM through extensive evaluations for occult malignancy. Recent studies have failed to demonstrate a clear association.6'56 A Mayo clinic series showed a slightly increased incidence of cancer in PM/DM patients but it was not statistically significant and seemed to be explained on the basis of referral bias.6 PM/DM had previously been linked to oat cell carcinoma of the lung, stomach and ovarian cancer and numerous other malignancies.57 A recent Canadian study found multiple methodological problems with previous studies showing these associations and although they found a higher frequency of neoplasms in PM/DM than in controls, these malignancies were found to be present at entry in the study and no statistically significant increase in subsequently diagnosed malignancy was ever found. 56 The question of association with malignancy must still be considered unanswered as is the dilemma ofhow extensive a 'cancer work-up' these patients should receive. Recent authors recommend a thorough history and physical examination as well as complete blood counts, multiphasic biochemical analysis of the blood, urinalysis, stool guaiac test and chest radiograph.58 '59 Further diagnostic tests should be directed by any abnormalities in these general screening tests.
Therapy
Before therapy is begun it is of utmost importance for the diagnosis to be accurate, the activity of the myositis assessed and the patient prepared for a somewhat long and, at its outset, frustrating therapeutic regimen. The latter includes physical therapy in periods of remission and rest periods in active myositis. Oral corticosteroids, in the form of prednisone in doses of 40-60 mg/day (1 mg/kg/day), is the backbone in the initiation therapy.2 This dose is continued for 1-2 months or until maximum benefit or disease remission is attained. The decision of when to begin tapering is usually made when improvement in muscle strength is seen and CK levels are declining. An important rule is that tapering must be slow. Mastaglia Five year mortality in PM/DM in numerous published series has ranged between 13.7% and 50%.1067 An actuarial study from Israel68 identified the following as independent unfavourable prognostic signs in PM/ DM: failure to induce remission, leucocytosis over 10,000/tlA, fever over 38°C, older age, a short disease history and dysphagia. The common denominator in a number of these risk factors was the development of aspiration pneumonia. Other factors, long thought to be signs of poor outcome, such as the presence of another autoimmune disease or of malignancy, duration and severity of PM/DM, degree of enzyme elevation or cardiac manifestations were not shown to be significant.68
Conclusion
Many questions remain unanswered in PM/DM. For the epidemiologist there is the problem of risk groups and inciting agents. For the immunologist there is the dissection of the exact mechanisms of immune injury. For the neurophysiologists there is the challenge of better non-invasive testing both for diagnosis and evaluation ofresponse to therapy, and for the clinician there are concerns about how extensively to look for cancer and how to treat. There is no consensus about the optimal starting dose ofprednisone, the timing and manner of dose reduction, the length of therapy in 'responders', the best means of evaluating response, the role ofpulsed methylprednisolone, the characteristics of 'steroid resistance' or the most appropriate use of immunosuppressants and other interventions.
